Character size
S
M
L
JPN
ENG
Contact Us
About Kaken
About Kaken TOP
Company Profile
Corporate Governance
History
Compliance
Environmental Initiatives
Map
Business
Business TOP
Pharmaceuticals and Medical Devices
Agrochemicals and Animal Health Products
Overseas Activity
Research & Development Division
Licensing Opportunities
Investor Relations
Investor Relations TOP
Consolidated Earnings Briefing
Consolidated Financial Results
Corporate Report
Shareholders' Meeting
Disclosure Policy
Press Release
About Kaken
Business
Investor Relations
Press Release
View All
April 27, 2022
Notice on KP-607, a Treatment for Onychomycosis
March 29, 2022
Announcement on Recording of Extraordinary Losses and Revisions to the Full-year Earnings Forecast
December 13, 2021
Kaken Completes Acquisition of ARTham Therapeutics Inc.
November 30, 2021
Notice on Acquisition of ARTham Therapeutics Inc.